Exova Group PLC Issue of Equity (3458X)
2016年5月5日 - 6:00PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMEXO
RNS Number : 3458X
Exova Group PLC
05 May 2016
EXOVA GROUP PLC
ISSUE OF EQUITY
Exova Group plc (the "Company") announces that application has
been made to the UK Listing Authority and the London Stock Exchange
for a listing of 58,823 new ordinary shares of 1 pence each (the
"Shares") in the Company for admission on 9 May 2016 to trading on
the main market for listed securities of the London Stock Exchange
and to listing on the premium listing segment of the Official List
maintained by the Financial Conduct Authority. The Shares will rank
pari passu with the existing ordinary shares of the Company.
The Shares were issued and allotted on 4 May 2016 to the Exova
Group Employee Benefit Trust to satisfy the exercise by Paul Barry,
a person discharging managerial responsibilities of the Company, of
his fully-vested award under the Company's Deferred Bonus Plan as
set out in the Company's RNS announcement dated 5 May 2016.
Following the issue of the Shares, the number of ordinary shares
in issue will increase to 250,431,550. For the purposes of the
Financial Conduct Authority's Disclosure and Transparency Rules
("DTRs"), the issued ordinary share capital of the Company
following this allotment consists of 250,431,550 Shares with voting
rights attached (one vote per Share). There are no Shares held in
treasury. This total voting rights figure may be used by
shareholders as the denominator for the calculations by which they
will determine whether they are required to notify their interests
in, or a change to their interest in, the Company under the
DTRs.
For and on behalf of Exova Group plc
Date: 5 May 2016
Neil MacLennan
General Counsel & Company Secretary
Telephone: 0131 333 8053
About Exova
Exova is one of the world's leading laboratory-based testing
groups, trusted by organisations to test and advise on the safety,
quality and performance of their products and operations.
Headquartered in Edinburgh, UK, Exova operates 145 laboratories and
offices in 32 countries and employs around 4,500 people throughout
Europe, the Americas, the Middle East and Asia/Asia Pacific.
Exova's capabilities help to extend asset life, bring
predictability to applications, and shorten the time to market for
customers' products, processes and materials. With over 90 years'
experience, Exova specialises in testing across a number of key
sectors from health sciences to aerospace, transportation, oil and
gas, fire and construction.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEAAMPTMBTMMAF
(END) Dow Jones Newswires
May 05, 2016 05:00 ET (09:00 GMT)
Exova (LSE:EXO)
過去 株価チャート
から 6 2024 まで 7 2024
Exova (LSE:EXO)
過去 株価チャート
から 7 2023 まで 7 2024
